Table 1. Baseline Demographics and Characteristics at Transplant.
| Characteristics | NO SALVAGE | SALVAGE | P-value |
|---|---|---|---|
| Number of patients | 215 | 324 | |
| Number of centers | 77 | 85 | |
| Baseline Demographics | |||
| Age at transplant, median (range) | 57 (33-75) | 56 (18-74) | |
| 18-39 | 13 (6) | 23 (7) | 0.872 |
| 40-49 | 40 (19) | 67 (21) | |
| 50-59 | 84 (39) | 113 (35) | |
| 60-69 | 70 (33) | 107 (33) | |
| 70- | 8 (4) | 14 (4) | |
| Male | 131 (61) | 200 (62) | 0.852 |
| KPS at diagnosis ≥80 | 177 (82) | 282 (87) | 0.293 |
| Immunoglobulin Subtype | |||
| IgG | 115 (53) | 175 (54) | 0.289 |
| IgA | 32 (15) | 66 (20) | |
| Light chain | 45 (21) | 59 (19) | |
| Othersa | 17 (8) | 15 (5) | |
| Missing | 6 (3) | 9 (2) | |
| Durie-Salmon Stage | |||
| Stage I | 17 (8) | 15 (5) | 0.093 |
| Stage II | 47 (22) | 61 (19) | |
| Stage III | 104 (48) | 150 (46) | |
| Missing | 47 (22) | 98 (30) | |
| International stage | |||
| Stage I | 49 (23) | 73 (23) | 0.375 |
| Stage II | 51 (24) | 68 (21) | |
| Stage III | 25 (12) | 55 (17) | |
| Missing | 90 (42) | 128 (40) | |
| Serum creatinine at diagnosis >1.5 mg/dL | 36 (17) | 86 (27) | 0.012 |
|
| |||
| No of lines of therapy | |||
| 1 | 215 (100) | 0 (0) | -- |
| 2 | 0 (0) | 245 (76) | |
| 3 | 0 (0) | 65 (20) | |
| ≥4 | 0 (0) | 14 (4) | |
| Sensitivity to second line chemotherapy | 197 (61) | ||
| Sensitivity to third line chemotherapy | 47 (59) | ||
| Sensitivity to fourth line chemotherapy | 2 (14) | ||
| VAD/Corticosteroid based first line therapy | 130 (60) | 152 (47) | 0.002 |
| Bort/Thal/Lena in first line therapy | 69 (32) | 126 (39) | 0.108 |
| Bort/Thal/Lena beyond first line | 186 (57) | ||
|
| |||
| Characteristics at Transplant | |||
| Disease status prior to transplant | |||
| CR | 0 (0) | 25 (8) | <0.001 |
| PR | 0 (0) | 196 (60) | |
| MR/NR/SD | 185 (86) | 88 (27) | |
| PROG/REL | 30 (14) | 15 (5) | |
| Sensitivity for chemotherapy (overall) | |||
| Sensitive | 0 (0) | 221 (68) | <0.001 |
| Resistant | 215 (100) | 103 (32) | |
| Time from diagnosis to HCT, median (range) | 7 (2-12) | 8 (3-12) | |
| <4 months | 76 (35) | 57 (18) | <0.001 |
| 4-8 months | 84 (39) | 85 (26) | |
| 8-12 months | 55 (26) | 182 (56) | |
| Number of transplants | |||
| Single transplant | 149 (69) | 219 (68) | 0.660 |
| Planned tandem transplantc | 38 (18) | 67 (21) | |
| Second salvage transplantd | 28 (13) | 38 (12) | |
| Time between first and second HCT | |||
| <6 months | 38 (58) | 67 (64) | 0.726 |
| 6-12 months | 6 (9) | 8 (8) | |
| 12-24 months | 3 (5) | 8 (8) | |
| 24-36 months | 4 (6) | 4 (4) | |
| >36 months | 15 (23) | 18 (17) | |
| Year of transplant | |||
| 1995-1996 | 18 (8) | 14 (4) | <0.001 |
| 1997-1998 | 41 (19) | 24 (7) | |
| 1999-2000 | 31 (14) | 22 (7) | |
| 2001-2002 | 24 (11) | 38 (12) | |
| 2003-2004 | 26 (12) | 44 (14) | |
| 2005-2006 | 32 (15) | 76 (23) | |
| 2007-2008 | 37 (17) | 85 (26) | |
| 2009-2010 | 6 (3) | 21 (6) | |
| Median follow-up of survivors (range), months | 68 (10-180) | 61 (9-181) | |
Follow-up completeness index as of 12/31/2010: @ 1 year (99%), @ 3 years (95%), @ 5 years (90%)
a
Other isotype:
line of chemotherapy=1: IgD (n=4), IgM (n=1), non-secretory (n=12)
line of chemotherapy>1: IgD (n=2), IgM (n=1), non-secretory (n=12)
b
Other conditioning regimsp:
line of chemotherapy=1: cyclophosphamide (n=1)
c
Planned tandem transplant: Planned and completed tandem transplant within 6 months after first transplant without relapse.
d
Secondary salvage transplant: Salvage 2nd transplant after relapse followed by 1st transplant.